NYSE$ALUR

Allurion Technologies Inc · Q4 2023 earnings

Q4 2023 earnings · · Investor relations

Briefing

Reported financial results for the fourth quarter and full year ended December 31, 2023, and reiterated 2024 guidance.

Allurion Technologies reported Q4 2023 revenue of $8.2 million, compared to $19.2 million for the same period in 2022. The company's cash and cash equivalents totaled $38 million as of December 31, 2023. They are reiterating the financial guidance it previously published for full year 2024.

  • Reiterated 2024 guidance on procedural volume, revenue, gross margin, and cash burn.
  • Fourth quarter revenue was $8.2 million and full year 2023 revenue was $53.5 million, consistent with preannouncement on January 8.
  • Procedural volume, as estimated through new app users, increased by 30% over 2022.
  • Completed enrollment in the AUDACITY pivotal trial ahead of schedule.

Headline financials

Total Revenue

$8.24M

Previous: $19.2M-57.1%
EPS (adj)

-$0.40

Previous: -$0.48+16.7%
Gross Margin

78.0%

No prior period
Capital Expenditures

$398K

Previous: $459K-13.3%
Net Income

-$19.2M

Previous: -$12.3M-55.3%
Operating Income

-$25.7M

Previous: -$10.1M-153.6%
Gross Profit

$6.43M

Previous: $15.2M-57.8%
R&D Expense

$6.07M

No prior period
Stock-Based Comp

$2.01M

Previous: $182K+1003.3%

Revenue & EPS history

Allurion · Revenue · Quarterly

$8.24M

Q4 2023-57.1%vs Q4 2022
Beat estimate in 5 of 8 quarters(63%)
ActualEstimate

Forward guidance

For full year 2024, Allurion reiterates the financial guidance it previously published:

Tailwinds

  • Anticipated procedural volumes growth of 20%, reflecting increased penetration in key direct markets and reallocation of marketing spend to more efficient channels
  • Revenue of $60 to $65 million, reflecting 12-22% growth year-over-year
  • Expected gross margins of 77-79%, reflecting durable pricing of our gastric balloon as well as initial commercialization efforts for the Allurion Virtual Care Suite SaaS product
  • Targeted cash burn of approximately $30 million for the full year

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2023

Historical avgQ4 2023

+1.5%

Avg return

Earnings day

+0.8%

Avg return

5 days after

+63.8%

Avg return

30 days after

48%

10 / 21 earnings

Positive

+47.1%

Q4 2025

Best reaction

-43.7%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q1 2026+25.0%+25.1%+1467.3%
Q4 2025+47.1%+35.3%+47.1%
Q3 2025+1.4%-6.0%+12.1%
Q2 2025+0.8%-8.1%-16.3%
Q1 2025+25.1%+29.7%+5.1%
Q4 2024+0.3%+3.2%-22.8%
Q3 2024-43.7%-46.2%-51.3%
Q2 2024-12.7%-17.0%-20.8%
Q1 2024-1.0%-8.8%-28.4%
Q4 2023-11.9%-11.0%-5.2%
Q3 2022+2.4%+0.7%-18.7%
Q3 2023+6.7%+2.4%-15.9%
Q2 2022-2.3%+3.8%-3.6%
Q1 2023-2.3%+3.8%-3.6%
Q2 2023-2.3%+3.8%-3.6%
Q4 2022-2.3%+3.8%-3.6%
Q1 2022+0.0%+0.2%+0.3%
Q4 2021+0.1%+0.3%-0.1%
Q3 2021-0.2%+0.0%+0.0%
Q2 2021-0.1%-0.5%-1.3%
Q1 2021+0.9%+1.0%+2.4%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro